Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®Business Wire · Oct 13, 2026
Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from BrokeragesDefense World · Oct 8, 2026
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall CongressBusiness Wire · Oct 6, 2026
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 2, 2026
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term CareBusiness Wire · Oct 1, 2026
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)Defense World · Sep 30, 2026Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.39 | -$0.40 | Miss |
| May 14, 2026 | -$0.41 | -$0.37 | Beat |
| Mar 26, 2026 | -$0.27 | -$0.30 | Miss |
| Nov 13, 2025 | -$0.43 | -$0.08 | Beat |
| Aug 14, 2025 | -$0.46 | -$0.65 | Miss |
| May 15, 2025 | -$0.58 | -$0.20 | Beat |